AzTrials
AzTrials

Acute Coronary SyndromePERFUSIONNCT04887571

the PrEsentation, Rationale and Impact of reperFUSION for Acute Coronary Syndromes in Cape Town and the Garden Route Health District - the PERFUSION Registry

An observational study of Acute Coronary Syndrome and ST Elevated Myocardial Infarction, run by University of Cape Town at 4 sites in South Africa.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The global burden and threat of non-communicable diseases (NCDs) have become a major health challenge that undermines social and economic development throughout the world. Cardiovascular disease including acute coronary syndromes (ACS) currently accounts for 17.9 million deaths a year. Read more about this study

Who is it for?
Ages 18 years and older
How many people
870 participants
Where
4 sitesSouth Africa
Study dates
1 Feb 2021to 31 May 2022
How long will I take part?
12 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study is designed to include adult patients from the Cape Metropole and the Garden Route Health District who present with acute coronary syndromes (STEMI, NSTEMI, or Unstable Angina).

Who may be able to join

  • signed written informed consent before any study recruitment; and
  • male or female patients age ≥ 18 years of age; and
  • a diagnosis of ACS (STEMI, NSTEMI or UA).

Who cannot join

  • ACS absent within index admission; or
  • refusal of consent

Trial locations and contacts

4 sites in 1 country.

South Africa4 sites
  • Groote Schuur Hospital

    Cape Town, Western Cape, 7295

  • Victoria Hospital

    Cape Town, Western Cape, 7800

  • New Somerset Hospital

    Cape Town, Western Cape, 8001

  • George Hospital

    George, Western Cape, 6529

Other trials in South Africa

About this study

The global burden and threat of non-communicable diseases (NCDs) have become a major health challenge that undermines social and economic development throughout the world. Cardiovascular disease including acute coronary syndromes (ACS) currently accounts for 17.9 million deaths a year. Low and middle-income countries such as those in sub-Saharan Africa (SSA) have undergone a rapid epidemiological transition over the last few decades and now have a burden of disease increasingly dominated by NCDs. The global burden of disease report for 2017 revealed a 71.4% increase in cardiovascular disease in SSA, predicting a large increase in mortality. Unfortunately, reliable population-level data regarding the incidence, prevalence and demographics of ACS in SSA are limited. The investigators propose to set up and conduct a multi-centre, prospective, observational registry to describe the demographics, clinical characteristics, presentation, management and outcomes of patients admitted with ACS in Cape Town and the Garden Route Health District, Western Cape Province, South Africa. The registry is designed to shed insight on the current burden and impact of atherosclerotic cardiovascular disease in the Western Cape.

Read the detailed description

The investigators propose to set up and conduct a multi-centre, prospective, observational registry to describe the demographics, clinical characteristics, presentation, management and outcomes of patients admitted with ACS in Cape Town and the Garden Route Health District, Western Cape Province, South Africa.

The aims of this prospective multi-centre registry are to describe the burden, demographics, risk factor profile, clinical course, management, and outcomes of patients presenting with ACS across the Cape Town metropole and the Garden Route Health District. The registry will be called "the PrEsentation, Rationale and impact of reperFUSION for Acute Coronary Syndromes in Cape Town - the PERFUSION registry". It will be designed to determine the feasibility of conducting a large multi-centre Acute Coronary Syndrome registry in South Africa.

Primary Objectives:

  1. to enrol consecutive patients presenting with acute coronary syndromes from designated participating sites;
  2. to describe the demographic and risk factor profile of participants with ACS;
  3. to describe the burden of patients presenting with ACS in the Cape Town metropole and the Garden Route Health District;
  4. to describe the management of patients with ACS and assess compliance with current South African guidelines;
  5. to describe the one month, six-month and 12-month outcomes with regard to all-cause mortality, hospitalisation, and major adverse cardiac events (recurrence of ACS, heart failure, stroke and ventricular tachy-arrythmias).

Methods:

Registry design The PERFUSION registry will enrol consecutive consenting adults (≥ 18 years) admitted to participating healthcare centres in the cities of Cape Town and the Garden Route Health District, Western Cape, South Africa. Depending on available capacity and resources, the registry may be expanded to other healthcare centres in the Western Cape and other provinces of South Africa.

As this is fundamentally an observational study, all participants enrolled will receive management based on local standard of care guidelines. Participant management will not be affected by recruitment into this study. By using the hub/ spoke/ pre-spoke model, all patients presenting with an ACS to a designated public healthcare care facility in the Cape Town metropole and the Garden Route Health District will be screened for study eligibility criteria. Screening will occur at hub and spoke levels only. Designated site PI's will identify potential study participants meeting eligibility criteria during their index ACS admission. Once screened according to the study's inclusion and exclusion criteria, potential participants will be consented for study participation. Clinical information fulfilling pre-defined registry variables will be entered into a standardised paper-based case report form (CRF) or electronic CFR and uploaded onto a secure data collection web application called the Research Electronic Data Capture (REDCap) by the study's data capturers. Upon data entry, participants will be immediately assigned a unique identifier generated by REDCap to maintain confidentiality. The REDCap database is governed by strict password-controlled access, assigned only to approved study team members.

Data collection:

The database variables collected for this registry are in line with the American College of Cardiology Foundation / American Heart Association Task Force on Key Data Elements. These include data pertaining to patient demographics; comorbidities and prior medication; index ACS presentation at the pre-spoke, spoke or hub level; ECG features; echocardiography; laboratory investigations; management and treatment received at the pre-spoke, spoke or hub level; angiography; complications of therapies and interventions; and outcomes (in-hospital, 1 month, 6 month and 1 year).

To limit an additional burden on the healthcare system, the investigators plan on following-up participants electronically using the Western Cape Provincial Health Data Centre (PHDC) and Single Patient Viewer (SPV) online tool over a period of 1-year after the index ACS presentation. The investigators have received both HREC and provincial permission for the utilisation of data from the PHDC and SPV for this research. Follow-up data will be uploaded directly onto REDCap and anonymised.

The key outcomes of interest will include:

  1. mortality (all-cause and cardiovascular);
  2. recurrent and re-infarction myocardial infarction;
  3. new-onset heart failure and arrhythmia complications;
  4. cerebrovascular events;
  5. major bleeding events;
  6. repeat hospitalisation for any cause.

The extended list of all variables collected will be found on the registry's CRF.

Benefits of registry participation:

Although there are no direct study benefits to the participant, the study will indirectly improve our knowledge of acute coronary syndromes in South Africa. By providing local reliable evidence in our resource constraint environment, the investigators may improve the standard of care provided to patients with ACS and possibly identify novel cardioprotective strategies that may help reduce the burden of ACS in South Africa.

Risk of registry participation:

The PERFUSION registry is designed to be a prospective, observational registry. Participant enrolment will not deviate management from local standard of care guidelines. There is no investigational medicinal product, drug or device practised in this protocol. Participation in this study has no physical, psychological, social, economic or legal risk. For people who do not want to take part in the study, routine standard of care will be maintained.

Being tested
No Intervention - Observational Registry
Keywords
Acute Coronary Syndrome, STEMI, NSTEMI, Unstable Angina, Sub-Saharan Africa, Cape Town, South Africa, Myocardial Infarction
Medical subject headings
Acute Coronary Syndrome, ST Elevation Myocardial Infarction, Non-ST Elevated Myocardial Infarction, Angina, Unstable, Myocardial Infarction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No Intervention - Observational RegistryOther

    All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an Acute coronary syndrome (STEMI, NSTEMI, Unstable Angina) will be recruited into the PERFUSION Registry.

Study groups in NCT04887571
Study groupRoleWhat they receive
Observational ACS RegistryAll consecutive adult patients in the Cape Metropole and the Garden Route Health District with an acute coronary syndrome will be recruited into the PERFUSION registry across the study duration.
Receives: Other: No Intervention - Observational Registry

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 1-year combined primary endpoint

    all-cause death, cardiac death, re-hospitalisation myocardial infarction, cerebrovascular accident

    Measured: 1 year

Secondary outcomes (5)
  1. cardiac adverse events

    re-hospitalisation for heart failure, or arrhythmias

    Measured: 1-year

  2. 1 month combined end point

    all-cause death, cardiac death, re-hospitalisation myocardial infarction, cerebrovascular accident

    Measured: 1-month

  3. 6 month combined end point

    all-cause death, cardiac death, re-hospitalisation myocardial infarction, cerebrovascular accident

    Measured: 6-month

  4. Compliance profile

    1-year compliance on guideline directed medical treatment

    Measured: 1-year

  5. Refusion time

    Time to ECG and reperfusion in patients with Acute Coronary Syndrome

    Measured: 1-year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2021
  2. Study start1 Feb 2021
  3. Primary completion31 May 2022
  4. Study completion31 May 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
870 participants (actual)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT04887571
Sponsor's protocol ID
PERFUSION
Acronym
PERFUSION
Status last verified
Jun 2023
First submitted
5 May 2021
Last updated
26 Jun 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Coronary Syndrome and ST Elevated Myocardial Infarction, run by University of Cape Town at 4 sites in South Africa.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

1-year combined primary endpoint (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in